Stocktoria
Genprex, Inc. GNPX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-03-29
Genprex, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | $0 |
| R&D expense | $9.4M | $10.5M | $17.6M | $11.5M | $9.0M |
| Operating income | -$15.5M | -$21.2M | -$31.1M | -$23.8M | -$20.7M |
| Income tax | $0 | $2,650 | $0 | $0 | — |
| Net income | -$16.2M | -$21.1M | -$30.9M | -$23.7M | -$20.7M |
| Operating cash flow | -$15.3M | -$17.9M | -$24.7M | -$17.6M | -$14.3M |
| Free cash flow | — | — | — | -$17.6M | -$14.3M |
| Cash & equivalents | $7.8M | $1.6M | $6.7M | $21.0M | $38.6M |
| Total assets | $10.2M | $4.1M | $10.7M | $25.1M | $42.9M |
| Total liabilities | $2.2M | $2.5M | — | — | $1.6M |
| Shareholders' equity | $8.0M | $1.6M | $7.4M | $22.3M | $41.3M |
Source: SEC EDGAR filings · CIK 0001595248 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.